IL1B and Alzheimer disease: Interestingly, AD patients have lower circulating levels of BHB [174, 175], and treatment of transgenic AD models with BHB reduces the levels of NLRP3 inflammasome-dependent ASC specks, cleaved caspase-1, and IL-1β while attenuating Aβ-plaque deposition [175].